Literature DB >> 19181789

Changing paradigms in the treatment of multiple myeloma.

Joan Bladé, Laura Rosiñol.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19181789      PMCID： PMC2635403          DOI： 10.3324/haematol.2008.002766

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  27 in total

1.  Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

Authors:  Frederic Garban; Michel Attal; Mauricette Michallet; Cyrille Hulin; Jean H Bourhis; Ibrahim Yakoub-Agha; Thierry Lamy; Gerald Marit; Frederic Maloisel; Christian Berthou; Mamoun Dib; Denis Caillot; Bernard Deprijck; Nicolas Ketterer; Jean-Luc Harousseau; Jean-Jacques Sotto; Philippe Moreau
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

2.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  S Vincent Rajkumar; Emily Blood; David Vesole; Rafael Fonseca; Philip R Greipp
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

3.  Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

Authors:  Bart Barlogie; Guido J Tricot; Frits van Rhee; Edguardo Angtuaco; Ron Walker; Joshua Epstein; John D Shaughnessy; Sundar Jagannath; Vanessa Bolejack; Jennifer Gurley; Antje Hoering; David Vesole; Raman Desikan; David Siegel; Jayesh Mehta; Seema Singhal; Nikhil C Munshi; Madhav Dhodapkar; Bonnie Jenkins; Michel Attal; Jean-Luc Harousseau; John Crowley
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

4.  Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

Authors:  Jean-Luc Harousseau; Michel Attal; Xavier Leleu; Jacques Troncy; Brigitte Pegourie; Anne-Marie Stoppa; Cyrille Hulin; Lofti Benboubker; Jean-Gabriel Fuzibet; Marc Renaud; Philippe Moreau; Hervé Avet-Loiseau
Journal:  Haematologica       Date:  2006-10-17       Impact factor: 9.941

5.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

6.  PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.

Authors:  Heather E Oakervee; Rakesh Popat; Nicola Curry; Pat Smith; Curly Morris; Mary Drake; Samir Agrawal; Jim Stec; David Schenkein; Dixie-Lee Esseltine; Jamie D Cavenagh
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

7.  Extramedullary multiple myeloma escapes the effect of thalidomide.

Authors:  Laura Rosiñol; Ma Teresa Cibeira; Joan Bladé; Jordi Esteve; Marta Aymerich; María Rozman; Marta Segarra; Maria C Cid; Xavier Filella; Emili Montserrat
Journal:  Haematologica       Date:  2004-07       Impact factor: 9.941

8.  Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.

Authors:  Bart Barlogie; Elias Anaissie; Frits van Rhee; Jeffrey Haessler; Klaus Hollmig; Mauricio Pineda-Roman; Michele Cottler-Fox; Abid Mohiuddin; Yazan Alsayed; Guido Tricot; Vanessa Bolejack; Maurizio Zangari; Joshua Epstein; Nathan Petty; Douglas Steward; Bonnie Jenkins; Jennifer Gurley; Ellen Sullivan; John Crowley; John D Shaughnessy
Journal:  Br J Haematol       Date:  2007-07       Impact factor: 6.998

9.  A comparison of allografting with autografting for newly diagnosed myeloma.

Authors:  Benedetto Bruno; Marcello Rotta; Francesca Patriarca; Nicola Mordini; Bernardino Allione; Fabrizio Carnevale-Schianca; Luisa Giaccone; Roberto Sorasio; Paola Omedè; Ileana Baldi; Sara Bringhen; Massimo Massaia; Massimo Aglietta; Alessandro Levis; Andrea Gallamini; Renato Fanin; Antonio Palumbo; Rainer Storb; Giovannino Ciccone; Mario Boccadoro
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245

10.  Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren; Paul W Dickman; Asa Rangert Derolf; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2007-04-09       Impact factor: 44.544
View more
  7 in total

1.  Novel drugs for the treatment of multiple myeloma.

Authors:  Joan Bladé; Ma Teresa Cibeira; Laura Rosiñol
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

2.  Oral status of patients submitted to autologous hematopoietic stem cell transplantation.

Authors:  Liana Leite Duval Fernandes; Sandra R Torres; Marcia Garnica; Lucio de Souza Gonçalves; Arley Silva Junior; Álvaro Copello de Vasconcellos; Wellington Cavalcanti; Angelo Maiolino; Maria Cynésia Medeiros de Barros Torres
Journal:  Support Care Cancer       Date:  2013-08-24       Impact factor: 3.603

3.  Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients.

Authors:  MaoFang Lin; Jian Hou; WenMing Chen; XiaoJun Huang; ZhuoGang Liu; YuHong Zhou; Yan Li; Taiyun Zhao; LinNa Wang; Kwang-Wei Wu; ZhiXiang Shen
Journal:  Adv Ther       Date:  2014-10-21       Impact factor: 3.845

4.  Current role of radiation therapy for multiple myeloma.

Authors:  Giampaolo Talamo; Christopher Dimaio; Kamal K S Abbi; Manoj K Pandey; Jozef Malysz; Michael H Creer; Junjia Zhu; Muhammad A Mir; John M Varlotto
Journal:  Front Oncol       Date:  2015-02-18       Impact factor: 6.244

5.  Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions.

Authors:  Jeong Won Lee; Jeong Eun Lee
Journal:  Radiat Oncol J       Date:  2016-03-30

6.  Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling.

Authors:  Jing Su; Le Zhang; Wen Zhang; Dong Song Choi; Jianguo Wen; Beini Jiang; Chung-Che Chang; Xiaobo Zhou
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

7.  Strategies to improve patient-reported outcome completion rates in longitudinal studies.

Authors:  Lene Kongsgaard Nielsen; Madeleine King; Sören Möller; Mary Jarden; Christen Lykkegaard Andersen; Henrik Frederiksen; Henrik Gregersen; Anja Klostergaard; Morten Saaby Steffensen; Per Trøllund Pedersen; Maja Hinge; Mikael Frederiksen; Bo Amdi Jensen; Carsten Helleberg; Anne Kærsgaard Mylin; Niels Abildgaard
Journal:  Qual Life Res       Date:  2019-09-23       Impact factor: 4.147
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.